Rubric Capital Discloses 2.9M Share Stake in Kiniksa Pharma
Ticker: KNSA · Form: SC 13G · Filed: 2024-02-12T00:00:00.000Z
Sentiment: bullish
Topics: institutional-ownership, sc-13g, investment-firm, pharmaceuticals
TL;DR
**Rubric Capital just revealed a big 2.9M share stake in Kiniksa Pharma, signaling institutional confidence.**
AI Summary
Rubric Capital Management LP, a Delaware-based investment firm, reported beneficial ownership of 2,907,501 Class A Common Shares of Kiniksa Pharmaceuticals, Ltd. as of December 31, 2023. This represents a significant stake, indicating Rubric's confidence in Kiniksa's future. For current or prospective shareholders, this filing signals that a professional investment firm sees value in Kiniksa, potentially validating their own investment thesis or prompting further research into the company's prospects.
Why It Matters
This filing shows a major institutional investor, Rubric Capital Management LP, has taken a substantial position in Kiniksa Pharmaceuticals, Ltd., which can be seen as a vote of confidence in the company's future.
Risk Assessment
Risk Level: low — This filing indicates an institutional investment, generally seen as a positive signal rather than a risk.
Analyst Insight
A smart investor would view this institutional filing as a positive signal and might conduct further due diligence on Kiniksa Pharmaceuticals, Ltd.'s fundamentals and future prospects, considering Rubric Capital Management LP's vote of confidence.
Key Numbers
- 2,907,501 — Class A Common Shares (The total number of Kiniksa Pharmaceuticals shares Rubric Capital Management LP beneficially owns.)
- December 31, 2023 — Reporting Date (The date as of which Rubric Capital Management LP's ownership stake is being reported.)
Key Players & Entities
- Rubric Capital Management LP (company) — the investment firm filing the SC 13G
- Kiniksa Pharmaceuticals, Ltd. (company) — the subject company whose shares are being reported
- 2,907,501 (dollar_amount) — number of Class A Common Shares beneficially owned
- December 31, 2023 (date) — date of the event requiring the filing
- Delaware (company) — place of organization for Rubric Capital Management LP
Forward-Looking Statements
- Other institutional investors may increase their positions in Kiniksa Pharmaceuticals, Ltd. following Rubric Capital Management LP's disclosed stake. (Kiniksa Pharmaceuticals, Ltd.) — medium confidence, target: Next 6-12 months
FAQ
What is the name of the reporting person in this SC 13G filing?
The reporting person is Rubric Capital Management LP, as stated on page 2 of 8 Pages, item 1.
What is the full name of the issuer whose securities are being reported?
The issuer is Kiniksa Pharmaceuticals, Ltd., as identified in the 'Name of Issuer' section of the filing.
How many Class A Common Shares of Kiniksa Pharmaceuticals, Ltd. does Rubric Capital Management LP have shared voting power over?
Rubric Capital Management LP has shared voting power over 2,907,501 Class A Common Shares, as indicated on page 2 of 8 Pages, item 6.
What was the date of the event which required the filing of this statement?
The date of the event which required the filing of this statement was December 31, 2023, as specified on the first page of the Schedule 13G.
What is the CUSIP Number for the Class A Common Shares of Kiniksa Pharmaceuticals, Ltd.?
The CUSIP Number for the Class A Common Shares is G5269C101, as listed on the first page of the Schedule 13G.
Filing Stats: 1,436 words · 6 min read · ~5 pages · Grade level 11.5 · Accepted 2024-02-12 06:06:38
Key Financial Figures
- $0.000273235 — Name of Issuer) Class A Common Shares, $0.000273235 par value per share (Title of Class of
Filing Documents
- tm245464d9_sc13g.htm (SC 13G) — 71KB
- 0001104659-24-013554.txt ( ) — 72KB
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of our knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct. DATED: February 12, 2024 RUBRIC CAPITAL MANAGEMENT LP By: /s/ Michael Nachmani Name: Michael Nachmani Title: Chief Operating Officer /s/ David Rosen DAVID ROSEN CUSIP No. G5269C101 13G Page 8 of 8 Pages EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. DATED: February 12, 2024 RUBRIC CAPITAL MANAGEMENT LP By: /s/ Michael Nachmani Name: Michael Nachmani Title: Chief Operating Officer /s/ David Rosen DAVID ROSEN